David A. Siegel Relay Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 394,300 shares of RLAY stock, worth $2.57 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
394,300
Previous 329,600
19.63%
Holding current value
$2.57 Million
Previous $3.63 Million
9.81%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RLAY
# of Institutions
188Shares Held
127MCall Options Held
4.2KPut Options Held
1.7K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$182 Million2.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.8MShares$63.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY7.42MShares$48.4 Million4.98% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.88MShares$44.9 Million0.01% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $784M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...